Placeholder Banner

BIO Applauds Advancement of Precision Medicine Initiative

February 26, 2016

Washington, D.C. (February 26, 2016) – The Biotechnology Innovation Organization (BIO) Executive Vice President for Health Policy Dan Durham released the following statement regarding yesterday’s White House announcement of actions to accelerate the Precision Medicine Initiative:

“Precision medicine holds great promise for many health care interventions to occur much earlier and with increased accuracy. We applaud this move to begin building a national, large-scale research participant group to accelerate precision medicine technologies. The data and discoveries resulting from this Initiative may play a critical role in enabling biopharmaceutical companies to develop treatments for patients before or early on in their disease progression, and with therapeutics that are far more effective and focused on the specific characteristics of their particular disease.

“We hope that as plans for the Initiative continue to take shape, Congress and the Administration will consider the tremendous potential of this research participant group to implement a multi-phase, multi-study, multi-year program to identify precursors and early signs of chronic diseases such as Alzheimer’s that threaten the health of our loved ones and undermine our nations’ own fiscal health. BIO proposed such a program as part of the 21st Century Cures Initiative.

“We look forward to working with the Administration and Congress to ensure that the discoveries and information resulting from the Initiative will serve to advance patient health and improve the drug development and review processes.”
 

Upcoming BIO Events 

BIO International Convention
June 6-9, 2016
San Francisco, Calif.

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

World Congress on Industrial Biotechnology
San Diego, CA
April 17-20, 2016

BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden


###

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…